Physician
Pediatrics at Oyster Point PLLC
Pediatrics at Oyster Point PLLC was paid $3.13M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoPEDIATRICS AT OYSTER POINT PLLC
NEWPORT NEWS, VA 23606
NEWPORT NEWS, VA 23606
33aNPI1801151741assigned 07/06/2012
33bProvider typePediatrics Physician
28Total paid$3.13M
24GClaims107,210
24DCodes billed68
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Virginia
Rank by total paid#56 of 817
Median peer was paid$29K
This provider vs. median107×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,938 | $211K | |
| 2019 | 13,169 | $371K | |
| 2020 | 14,339 | $371K | |
| 2021 | 17,917 | $422K | |
| 2022 | 16,872 | $463K | |
| 2023 | 18,281 | $593K | |
| 2024incomplete | 20,694 | $699K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 9,732 | 8,277 | $790K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 9,334 | 8,250 | $576K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 13% | 5,536 | 4,886 | $414K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 10% | 4,113 | 4,058 | $327K |
| 90671 | 4.4% | 1,471 | 1,433 | $138K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.6% | 1,486 | 1,466 | $113K |
| 90698 | 2.1% | 2,985 | 2,900 | $64K | |
| 92552 | 1.8% | 2,057 | 2,026 | $56K | |
| 90670 | 1.7% | 2,349 | 2,289 | $55K | |
| 90680 | 1.6% | 2,507 | 2,433 | $51K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 6,444 | 6,257 | $49K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.5% | 597 | 580 | $46K |
56 more codes
| 99188 | 1.0% | 1,528 | $32K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.0% | 14,526 | $31K |
| 90716 | <1% | 1,151 | $31K | |
| 99381 | <1% | 358 | $29K | |
| 87428 | <1% | 821 | $29K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,008 | $26K |
| 90707 | <1% | 1,198 | $25K | |
| 90686 | <1% | 1,958 | $24K | |
| 90633 | <1% | 1,640 | $24K | |
| 90744 | <1% | 1,836 | $24K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 157 | $19K |
| 90461 | <1% | 5,446 | $13K | |
| 99174 | <1% | 2,476 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 944 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 298 | $11K |
| 90651 | <1% | 188 | $11K | |
| 99401 | <1% | 766 | $10K | |
| 81003 | <1% | 4,366 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 271 | $9K |
| 87807 | <1% | 474 | $6K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 680 | $6K |
| 96161 | <1% | 2,691 | $6K | |
| 90381 | <1% | 34 | $5K | |
| 99383 | <1% | 42 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 330 | $4K |
| 90734 | <1% | 121 | $4K | |
| 90656 | <1% | 223 | $3K | |
| 96127 | <1% | 700 | $3K | |
| 99173 | <1% | 1,322 | $3K | |
| 90700 | <1% | 190 | $3K | |
| 90619 | <1% | 59 | $3K | |
| 99000 | <1% | 1,184 | $3K | |
| 90696 | <1% | 171 | $3K | |
| 0071A | <1% | 60 | $2K | |
| 0072A | <1% | 52 | $2K | |
| 90648 | <1% | 170 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,020 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $2K |
| 90715 | <1% | 73 | $1K | |
| 99382 | <1% | 13 | $1K | |
| 90380 | <1% | 13 | $1K | |
| 36416 | <1% | 6,270 | $846.20 | |
| 96380 | <1% | 38 | $589.30 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 34 | $512.77 |
| 0001A | <1% | 12 | $488.00 | |
| 81002 | <1% | 151 | $382.24 | |
| 90660 | <1% | 16 | $281.80 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 14 | $202.90 |
| 81000 | <1% | 57 | $186.33 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 15 | $66.24 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 16 | $19.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $17.26 |
| 91300 | <1% | 111 | $4.83 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 16 | $0.35 |
| 91307 | 0% | 144 | $0.00 | |
| 99051 | 0% | 118 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUTCHER, BRIAN (MANAGING PARTNER)